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ABSTRACT  
Background and Objectives: Haematological malignancies account for approximately 40% of all cancers by the age of 15 years. Acute 
leukaemia (AL) account for one-third of childhood cancer cases; consisting of Acute Lymphoblastic Leukaemia (ALL) and Acute Myeloid 
Leukaemia (AML). The aim of this work is to describe the epidemiological, clinical, biological and evolutionary characteristics of children with 
acute leukaemia in the western and south-western region of Algeria. 
Patients and Methods: A three-year retrospective study was undergone from January 2016 to December 2018 on children with acute 
leukaemia. The study was conducted at the paediatric oncology department of the anti-cancer -Emir AEK- of Missreghine in Oran. 
Results: During this period, we identified 135 cases of diagnosed AL. The sex ratio M/F was 1.1. The “two to five-year” age group was the most 
affected. The prevalence of ALL, AML, and biphenotypic acute leukaemia (BAL) was 60.45%, 23.88%, and 15.57%, respectively. The clinical 
signs were mainly presented by the tumour syndrome dominated by the presence of lymphadenopathy (63%) and splenomegaly (56.3%). The 
most frequent abnormal blood abnormalities were anaemia (66.66% in ALL and 28.14% in AML), thrombocytopenia (75.9% in ALL and 24.4% 
in AML) and leukocytosis (76.3% ALL and 23.7% AML). 
Conclusion: Paediatric acute leukaemia is a real public health problem that requires special care and attention. This management must involve 
all epidemiological, clinical and biological aspects for this highly sensitive age group. 
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INTRODUCTION 
Haematological malignancies account for about 40% of all 
cancers by the age of 15. Acute leukaemia remains the most 
common malignant tumour in children and represents one-
third of paediatric cancers.1, 2 In Europe and the US, AL 
accounts for 80% of leukaemia and about 35% of childhood 
cancers.3 Acute leukaemia are a group of hematologic 
disorders characterized by malignant proliferation and 
accumulation of a large number of clonal modularly 
precursors (blasts) of blood lines, blocked at a specific stage 
of differentiation that are found in the marrow, blood and 
sometimes other tissues. Depending on the line concerned, 
they are subdivided into acute myeloid leukaemia (AML) 
and acute lymphoblastic leukaemia (ALL).4 In children, 80% 
of acute leukaemia is called lymphoid or lymphoblastic 
(ALL). Of these cases, 80% are LALs of line B (affecting the 
development of B lymphocytes), called common.5 AML is 
relatively rare in childhood, accounting for 15% to 20% of 
AL, but the most prevalent among adults.6 Epidemiological 
studies of acute childhood leukaemia have examined risk 
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factors, including genetic, infectious and environmental 
factors. The majority is idiopathic: no identified cause.7, 8 The 
clinical presentation of acute leukaemia results from 
infiltration of bone marrow or extramedullary sites by 
explosions. As a result, the first symptoms may be due to the 
presence of anaemia, neutropenia or thrombocytopenia. All 
tissues and organs can be affected, including ganglia, spleen 
and liver.9 
Since these first descriptions, the diagnosis of ALL and AML 
is made on cytological and immunological criteria of bone 
marrow blasts. The contributions of immunophenotyping, 
cytogenetics and finally molecular biology have made it 
possible to describe more and more AL entities from one 
patient to another.10, 11 
The therapy differs considerably depending on the type of 
leukaemia developed in the child. It is risk-based optimizes 
the healing potential while minimizing risks and side effects. 
All acute leukaemias are treated with chemotherapy, but the 
treatment can be adapted, more intensive, for the most 
serious forms with sometimes a bone marrow transplant.5 
The aim of this work is to describe the epidemiological, 
clinical, biological and evolutionary characteristics of 
children with acute leukaemia in the western and south-
western region of Algeria, in the service of paediatric 
oncology of the anti-cancer centre -Emir AEK- Misserghine 
in Oran, north western Algeria. 
METHODS 
Objectives of the study 
The objective of this study is to describe the clinical, 
biological and evolutionary characteristics of children with 
acute leukaemia in the West and South-West of Algeria. 
Type of study 
The study that we conducted is a retrospective descriptive 
and cross-sectional study, involving 135 files of patients who 
were treated for acute leukaemia in the Paediatric Oncology 
Department of the anti-cancer centre -Emir AEK- Misseghine 
in Oran, during the period from January 2016 to December 
2018. The processing of the files covered duration of 3 
months, from February 2019 to May 2019. 
Characterization of the population  
Our work is carried out on a population included all the 
patients aged 1 month to 16 years, of both sexes suffering 
from acute leukaemia, and coming from several regions of 
West and Southwest Algeria (Oran, Sidi-Bel-Abbes, Chlef, 
Bechar, Adrar, Ain Timouchent, El Bayadh, Mascara, 
Mostaganem, Naama, Retizane, Saida, Tiaret, Tlemcen and 
Tissemsilt). 
Criteria for diagnosis  
Only patients whose definitive diagnosis was made in the 
paediatric oncology department by a symptomatic clinical 
examination of more or less complete insufficiency (Anaemic 
syndrome and/or infectious syndrome and/or syndrome 
hemorrhagic) with or without tumour syndrome 
(splenomegaly, hepatomegaly, lymphadenopathy, gingival 
hypertrophy, bone pain) and paraclinical examination with 
specimens in the laboratory haematology based on 
biological and/or histological examinations: the blood count, 
morphological examination of blood smears, and a study of 
the medullogram (a medullar blast cell count ≥ 20%). 
However, patients benefit from cytometric confirmation by 
flow cytometry (CMF). 
Data collection 
For the collection of data, we used the medical file of the 
patient, to fill out a record of exploitation which aims to 
specify the epidemiological, clinical, biological and 
evolutionary aspects of each patient admitted for AL. The 
parameters on which our study focused are:  
1. Age, sex, usual residence and anthropometric 
parameters (height, weight, BMI). 
2. Clinical information that pertains to antecedents 
(family, inbreeding between parents and personal 
history), reason for consultation, consultation time and 
symptoms.  
3. Radiological data: Chest X-ray and abdominal 
ultrasound.  
4. Biological data they concern: 
a. The hemogram 
b. Peripheral blood smear (blood film) 
c. Biochemical assessment 
d. Assessment of haemostasis 
e. Medullogram 
f. Lumbar puncture (LP) 
g. Flow cytometry 
5. Therapeutic aspects: 
a. Start date of treatment induction  
b. Evaluation date with the result of the medullogram 
exam 
6. Evolutionary aspects: Remission, Relapse, Death, Lost 
of sight. 
Statistical analyzes 
The statistical analysis is based on the use of the SPSS 22 
software (Statistical Package for the Social Sciences, IBM 
Corporation, Chicago, IL, August 2013). Quantitative 
variables by groups were compared by Student's "t" test. 
Only significant differences at the 5% level were retained. 
Whereas, the Chi-square test was used for studying 
qualitative variables. 
RESULTS 
During the study period, 135 cases of diagnosed LA were 
identified (96 ALL and 39 AML), the sex ratio M/F in all 
participants was 1.1. The two to five-year age group was the 
most affected in both males and females (table 1). However, 
no significant differences were revealed between the two 
genders regarding all the studied parameters (age, 
anthropometric parameters, family history and 
consanguinity).  
The comparison of clinical parameters between ALL and 
AML are summarized in table 2. As sign of spinal cord 
impairment, the infectious syndrome was significantly 
higher in ALL (p<0.001) comparing to AML patients. 
Furthermore, regarding the tumor syndrome, the 
splenomegaly (p=0.002) and the inguinal lymphadenopathy 
(p=0.044) were significantly frequent in ALL comparing to 
AML. No case of monocytic anemia has been recorded in 
AML group. However, higher significant positive (p=0.045) 
cytochemical staining was recorded in AML patients.  
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Table 3 highlight the comparison of biochemical parameters 
between the groups. Higher significant rates of lymphocytes 
and platelets were observed in ALL patients (p=0.031 and 
p=0.026, respectively) comparing to higher levels of 
neutrophils (p=0.002) and MCH (p=0.013) in AML patients. 
As a very important parameter, the blast rate was 
significantly higher in ALL comparing to AML patients 
(p<0.001).   
We also evaluated progressive aspect of the disease 
(presence of blasts, risk, clinical remission, loss of sight and 
death) in our study patients (table 4). Low rates of blats 
were observed in the two groups. The risk was higher in 
both ALL and AML with no significant difference. The loss of 
follow-up frequency was low in the two patients’ groups. 
However, the general rate of death was about 11% in the 
both ALL and AML patients. 
 
 
Table 1: Basic characteristics of participants 
 All patients (n=135) Males (n=72) Females (n=63) p value * 
Age (years), mean±SD 6.20±3.99 6.24±4.19 6.16±3.78 0.912 
Weight (kg), mean±SD 20.10±10.67 20.59±11.48 19.52±9.71 0.563 
High (cm), mean±SD 103.63±23.23 104.32±24.86 102.83±21.39 0.711 
Age group (years), n (%) 
 2  20 (14.8) 11 (8.1) 9 (6.7) 
0.274 
2 and  5  51 (37.8) 28 (20.7) 23 (17.0) 
 5 and  12 49 (36.3) 22 (16.3) 27 (20.0) 
 12 15 (11.1) 11 (8.1) 4 (3.0) 
Type of leukaemia, n (%) 
ALL 96 (71.1) 48 (35.6) 48 (35.6) 
0.223 
AML 39 (28.9) 24 (17.8) 15 (11.1) 
Family history, n (%) 
Yes 15 (11.9) 9 (6.7) 6 (4.4) 
0.583 
No 120 (88.9) 63 (46.7) 57 (42.2) 
Consanguinity, n (%) 
Yes 27 (20.0) 13 (9.6) 14 (10.4) 
0.546 
No 108 (80.0) 59 (43.7) 49 (36.3) 
(*) Comparison between males and females; mean values were compared using Student’s t-test. Percentages were compared 
with Chi-square test, a p<0.05 was considered as significant; ALL: Acute Lymphoblastic Leukaemia; AML: Acute Myeloid 
Leukaemia.  
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Table 2: Comparison of clinical parameters between ALL and AML 
 
ALL (n=96) 
 
AML (n=39) p value * 
Signs of spinal cord impairment, n (%) 
Anemic syndrome 
No 6 (4.4) 1 (0.7) 
0.381 
Yes 90 (66.7) 38 (28.1) 
Infectious syndrome 
No 29 (21.5) 25 (18.5) 
<0.001 
Yes 67 (49.6) 14 (10.4) 
Hemorrhagic syndrome 
No 45 (33.3) 12 (8.9) 
0.086 
Yes 51 (37.8) 27 (20.0) 
Fever 
No 56 (41.5) 22 (16.3) 
0.838 
Yes 40 (29.6) 17 (12.6) 
Arthralgia 
No 61 (45.2) 25 (18.5) 
0.951 
Yes 35 (25.9) 14 (10.4) 
Asthenia 
No 40 (29.6) 13 (9.6) 
0.369 
Yes 56 (41.5) 26 (19.3) 
Paleness 
No 16 (11.9) 7 (5.2) 
0.857 
Yes 80 (59.3) 32 (23.7) 
Tumor syndrome, n (%) 
Splenomegaly 
No 34 (25.2) 25 (18.5) 
0.002 
Yes 62 (45.9) 14 (10.4) 
Hepatomegaly 
No 51 (37.8) 26 (19.3) 
0.150 
Yes 45 (33.3) 13 (9.6) 
Axillary lymphadenopathy 
No 59 (43.7) 30 (22.2) 
0.086 
Yes 37 (27.4) 9 (6.7) 
Inguinal lymphadenopathy 
No 59 (43.7) 31 (23.0) 
0.044 
Yes 37 (27.4) 8 (5.9) 
Cervical lymphadenopathy 
No 45 (33.3) 17 (12.6) 
0.728 
Yes 51 (37.8) 22 (16.3) 
Gingival lymphadenopathy 
No 89 (65.9) 36 (26.7) 
0.936 
Yes 7 (5.2) 3 (2.2) 
Testicular lymphadenopathy 
No 96 (71.1) 38 (28.1) 
0.115 
Yes 0 (0.0) 1 (0.7) 
Cytopenia, n (%) 
Pancytopenia 
No 73 (54.5) 30 (22.4) 
0.992 
Yes 22 (16.4) 9 (6.7) 
Bicytopenia 
No 32 (23.9) 10 (7.5) 
0.362 
Yes 63 (47.0) 29 (21.6) 
Leucocytosis 
No 36 (47.0) 29 (21.6) 
0.362 
Yes 32 (23.9) 10 (7.5) 
Anaemia type, n (%) 
Macrocytic anaemia 10 (7.5) 0 (0.0) 
0.035 
Hypochromic microcytic anaemia 85 (63.4) 40 (29.62) 
Cytochemical staining, n (%) 
Negative 96 (71.1) 13 (9.6) 
0.045 
positive 0 (0.0) 26 (19.3) 
(*) Comparison between ALL: Acute Lymphoblastic Leukaemia; AML: Acute Myeloid Leukaemia using Chi-square test, a p<0.05 
was considered as significant. 
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Table 3: Comparison of biological parameters and blast rate between ALL and AML 
 ALL (n=96) 
 
AML (n=39) p value * 
White blood cells, 103/mm3 34.75±5.47 27.54±3.25 0.443 
Lymphocytes, 103/mm3 19.29±2.72 9.44±1.08 0.031 
Neutrophils, 103/mm3 6.04±1.27 16.64±2.56 0.002 
Red cells, 106/mm3 2.76±0.73 2.68±0.50 0.491 
Haemoglobin, g/dl  8.02±1.97 8.28±1.46 0.449 
Mean corpuscular volume, FL 85.67±6.49 86.27±12.15 0.708 
MCHC, g/dl 33.75±2.72 34.24±2.65 0.350 
MCH, gp 29.05±2.81 30.47±3.30 0.013 
Platelet, 103/mm3 67.93±7.94 38.56±2.53 0.026 
Blast rate per myelogram, % 83.92±1.68 60.10±2.40 <0.001 
(*) Comparison between ALL: Acute Lymphoblastic Leukaemia; AML: Acute Myeloid Leukaemia using Student t test, a p<0.05 
was considered as significant; MCHC: mean corpuscular hemoglobin concentration; MCH: mean corpuscular hemoglobin. 
 
Table 4: Evolutionary characteristics for all participants between 2016 and 2018 
 ALL (n=96) 
 
AML (n=39) (%) p value * 
Lumbar puncture, n (%) 
Normal 95 (70.4) 38 (28.1) 
0.507 
Presence of blasts 1 (0.7) 1 (0.7) 
Risk, n (%) 
Very high 32 (25.8) 17 (13.7) 
0.100 
Moderate 59 (47.6) 16 (12.9) 
Clinical remission, n (%) 
No 68 (50.4) 30 (22.2) 
0.472 
Yes 28 (20.7) 9 (6.7) 
Lost of follow-up, n (%) 
No 95 (70.4) 36 (26.7) 
0.039 
Yes 1 (0.7) 3 (2.2) 
Death, n (%) 
No 80 (59.3) 24 (17.8) 
0.006 
Yes 16 (11.9) 15 (11.1) 
(*) Comparison between ALL: Acute Lymphoblastic Leukaemia; AML: Acute Myeloid Leukaemia using Chi-square test, a p<0.05 
was considered as significant. 
 
DISCUSSION 
Data from the medical literature report that child's AL, 
although rare in itself, is the leading cause of pediatric 
cancer (30%) and occurs mostly before the age of 9 years. In 
Europe and the United States, ALLs account for 75 to 80% of 
leukaemia and about 20% of cancers in children under 15 
years of age.12 There are two main types of AL; ALL and AML. 
In our series, 135 cases of children with AL were recorded 
during the period from January 2016 to December 2018. The 
distribution of ALL and AML and biphynotypic AL reveals a 
predominance of ALL with 60.45% of cases, followed by 
AML (23.88%). The prevalence of biphynotypic leukaemia is 
in the order of 15.67%. These results are in agreement with 
the statistics of the Ibn-Sina University Hospital Centre.10 
We recorded a sex ratio M/F of 1.1 vis-à-vis acute leukaemia 
(both types combined). This male dominance has also been 
observed in several other studies including the investigation 
of "frequency of childhood leukaemia in Qazvin province" 
and its correlation with sex, age and blood groups between 
2006-2016 where sex ratio M/F was 1.24.13 Similarly, in 
2016, Doumbia et al. noted the same observations with a sex 
ratio M/F of 1.08 (10). In contrariwise, Cumin et al. (1995) 
reported a sex ratio of 0.79 in favour of females.14 
The age is an important prognostic factor; it is associated 
with poor progression when it is less than 1 year or older 
than 10 years.15 In the UK, the incidence is 30 per million 
children a year. This incidence is greatest between the age of 
2 and 5 years.16 In France, the annual incidence is 137 per 
million children under 15 years of age.17 The highest rates 
are found in male children and children aged 1-4 years.18 
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In our study, the highest prevalence of AL was recorded for 
the 2- to 5-year and 5 to 12-year age groups with a 
predominance of ALL. Dargahi et al. (2016) reported the 
same results.13 
The present study revealed that the duration between onset 
of symptom and diagnostic confirmation was about 50 days 
for ALL is almost 40 days for AML. This situation was 
described by Roganovic in 2013; "The symptoms can vary 
from a few days to a few months and often accumulate in a 
few days or weeks and result in an event that brings the child 
to medical attention."19 
In our case, most children had symptoms for 3-4 weeks. The 
symptoms and signs presented correlate with leukaemia cell 
load and the degree of bone marrow replacement, leading to 
cytopenia. The initial presentation includes the 
manifestations of the main clinical signs of bone marrow 
failure that have been reported by several studies. 
According to Esparza & Sakamoto (2005),20 common 
constitutional symptoms include fever (60%), fatigue (50%) 
and pallor (25%). In our children, clinical signs were 
recorded in 90.4% of patients (94 cases) with fever in 61% 
of cases and hemorrhagic syndrome in 50% of cases. 
Anaemia at the time of diagnosis was present in most of our 
patients (85%), which corroborates the findings of Pérez et 
al. (2018).21 
However, the most common manifestations in our study 
were fever (55.8%) and pallor (53.7%). Hemorrhagic 
complications are common in patients with acute leukaemia 
(approximately 20%). 
Tumour syndrome is the result of the infiltration of different 
hematopoietic organs or even other organs by blast cells. It 
is more common in ALL than in AML resulting in 
hepatomegaly, splenomegaly, lymphadenopathy, bone pain, 
skin infiltrates and swollen gums. This syndrome was mainly 
present in our series in the form of adenopathies (63% of 
cases), splenomegaly was found in 56.30% of cases and 
hepatomegaly in 43% of cases. Bone involvement, which can 
manifest as spontaneous bone pain, was found in 36.30% of 
cases. 
This situation is frequently encountered in other studies: in 
the study by Sall et al. (2015), splenomegaly was present in 
more than 75% of cases, associated with symmetrical 
lymphadenopathy rarely bulky while hepatomegaly was 
present in half of the cases.22 In their works, Acharya et al. 
(2018),23 hepatomegaly was the most common presentation 
(95%), followed by splenomegaly (77%), lymphadenopathy 
(58%) and arthralgia (17.5%). 
Osteo-articular manifestations are an infrequent form of 
revelation of AL of the child, representing about 14% of 
cases, sometimes before the appearance of haematological 
signs.24 
The hemogram which directs towards the diagnosis of the 
AL, shows most often the attack of three lineages; white, red 
and platelet. It was performed in all patients in this study. 
Many studies show physiological variations in the blood 
count data. A high number of white blood cells (WBCs) (> 
10,000/mm3) occurs in about half of the children, with 20% 
showing that the initial WBC level is greater than 
50,000/mm3. Normochromic and normocytic anemia 
(hemoglobin <10 g/dL) occurs in approximately 80% of 
children. Thrombocytopenia (platelet count <100,000 / 
mm3) occurs in 75% of children at diagnosis. Spontaneous 
bleeding occurs in patients with less than 20,000-30,000 
platelets/mm3.19 
In our series, 29 patients had a WBC rate greater than 50 
000/mm3, of which 20 cases (76.3%) of ALL and 9 cases 
(23.7%) of AML. Those with profound leukocytosis with 
neutropenia account for 82.9% of ALL and 17.1% of AML. 
The presence of anaemic syndrome with a haemoglobin 
level between 7 and 10 g/d was recorded in 69% of ALL 
patients and 30.7% of AMLs. 
The myelogram allows the diagnosis of AL when the marrow 
is invaded by at least 20% of abnormal blasts, in practice 
often more than 80% of AL. In our series, we found a highly 
significant difference (p <0.001) between the two types of 
leukaemia with respect to blast content: in ALL (83.92 ± 
16.89%) was significantly elevated compared to blast levels 
in AML (60.10 ± 24.05%). These results are similar to those 
of Doumbia et al. (2016).10 
Immunophenotyping has become an essential step in the 
diagnosis of acute leukaemia, it makes it possible to confirm 
the cell line involved in the leukemic process, and to specify 
the blocking stage of blasts in their differentiation.25 
Lumbar puncture examination was normal in the vast 
majority of cases for ALL (70%) or AML (28.15%) with a 
clear appearance. These findings were also reported by 
Mwirigi et al., 2017, who found leukemic infiltration of the 
central nervous system in less than 10% of patients with 
ALL.26 
The treatment of childhood leukaemia has changed 
dramatically over the past 50 years. The overall cure rate is 
80% with variations depending on the different AL subtypes. 
Several studies show results about the evolution of AL. 
During the course of our study, we recorded a complete 
remission in the vast majority of cases (51 cases), followed 
by relapses (28 cases) and death (16 cases) and we recorded 
a single case of lost sight. In parallel, 15 cases of death were 
recorded for AML leukaemia, 11 cases of complete remission 
and 9 cases of relapse. Several authors have noted nearly 
similar results.10, 27 
CONCLUSIONS 
Our results reveal that LA in children in the west and 
southwest region of Algeria is increasing alarmingly. The 
characteristics of our population are similar to the data in 
the literature on clinical, biological and evolutionary levels 
without a specific unusual feature for our region. The 
management of this disease must bring together all 
stakeholders in public health professionals and must 
integrate the local and regional networks of pediatric cancer 
care. Indeed, the specificity of the care of children with 
cancer must build a national and an international strategy. 
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